Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: Aug 07, 2015

First accelerator of nanobiomedicine projects launches

(Nanowerk News) The EU-funded consortium ENATRANS (Enabling Nanomedicine TRANSlation) launches the first Translation Advisory Board (TAB), a new instrument to provide free of charge advice and support to ambitious international nanobiomedicine projects.
The call is open to companies, academics and private researchers in Europe promoting nanobiomedicine projects. First-in-class recognized experts from industry will deliver concrete and invaluable advice to drive selected nanobiomedicine projects into innovative products for healthcare. Among those ambitious projects, the most promising will benefit from further high value services such as in-depth advice, showcase and coaching (check the flyer here).
The applicants must have very promising nanobiomedicine projects, targeting unmet medical need for patients.
Do you have an ambitious nanobiomedicine project? Apply and benefit from high level experts support here.
Applications received till September 14, 2015 may be eligible for the first TAB-in session, which will gather selected projects in a first phase of the service to be organised in Dublin, October 14, 2015.
Who are the experts?
Paul Smit - former senior position at Philips Healthcare, Mike Eaton - former senior positions at Celltech, UCB David Bott - former senior position at BP, Ruediger Iden - former senior position at BASF, Eckhard Schwenner - former position at Bayer, Eric Mayes - CEO at Endomag, Laurent Levy - CEO at Nanobiotix.
About the ENATRANS project
Enabling NAnomedicine TRANSlation, a Coordination and Support Action funded by the European Commission, has been built to help the translation of innovative projects related to nanomedicine to successfully go through the different stages of development from the idea to the patients and also improve global knowledge on nanomedicine. ENATRANS is led by a consortium of 7 partners belonging to the European Technology Platform for Nanomedicine (ETPN): CEA-LETI (Grenoble, France), Nanobiotix SA (Paris, France), Gesellschaft fur Bioanalytik Muenster e.V. (Muenster, Germany), Tel-Aviv University (Tel-Aviv, Israel), Fondazione Don Carlo Gnocchi ONLUS (Milan, Italy), TecMinho (Braga, Portugal) and VDI/VDE-IT (Berlin, Germany).
About ETPN
Created in 2005, the European Technology Platform for Nanomedicine is an initiative led by Industry and set up together with the European Commission to address the applications of nanotechnology to achieve breakthroughs in healthcare. The ETPN is structuring and federating the European Nanomedicine community and leading the communication toward the European Commission and the European Members States.
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
These articles might interest you as well: